Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).

Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).

Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).

Abstract: Compositions and methods are provided which are useful in determining the levels of the C-telopeptide of human Type I collagen. The levels of the C-telopeptide are used as a marker of collagen degradation in an individual, and thus serve as a sensitive and specific indicator of bone resorption. Assays for the C-telopeptide find a variety of uses, including use in diagnosing metabolic bone disorders such as osteoporosis or postmenopausal rapid bone losers, monitoring the efficacy of therapeutic regimens designed to treat such disorders, determining the extent of imbalances between bone formation and resorption.

Abstract: The present invention provides methods for separating ligands from binding proteins. The methods include acidic separation and size separation. The methods of the present invention are particularly useful for separating insulin-like growth factors from insulin-like growth factor binding proteins.

Abstract: The present invention relates to an improved method of treating osteopenias, particularly osteoporosis, in mammals comprising administering a therapeutically effective amount of a pharmaceutical formulation agent comprising the polypeptide Insulin-like Growth Factor II or an osteoblastic stimulating fragment thereof, either alone or in the presence of a potentiating amount of fluoride ion, and in a pharmaceutically acceptable carrier.The invention further relates to a method of preventing osteopenias in a susceptible population of mammals consisting of administering a prophylactically effective amount of the pharmaceutical agent described above.

Abstract: Compositions and methods are provided which are useful in determining the levels of the C-telopeptide of human Type I collagen. The levels of the C-telopeptide are used as a marker of collagen degradation in an individual, and thus serve as a sensitive and specific indicator of bone resorption. Assays for the C-telopeptide find a variety of uses, including use in diagnosing metabolic bone disorders such as osteoporosis or postmenopausal rapid bone losers, monitoring the efficacy of therapeutic regimens designed to treat such disorders, determining the extent of imbalances between bone formation and resorption.

Abstract: The invention provides homogeneous compositions of a binding protein for insulin-like growth factors (IGFs) I and II, which binding protein inhibits the proliferative effects of IGF-I and IGF-II upon bone cells. The homogeneous protein of the invention is therefore known as inhibitory IGF binding protein, or In-IGF-BP. The invention also provides cloned nucleic acid sequences encoding In-IGF-BP, artificial expression systems for In-IGF-BP and host cells which produce useful quantities of In-IGF-BP. The invention further provides clinical diagnostic assays for IGFs, therapeutic treatments for IGF-responsive tumors, and means for modulating IGF activity upon bone cells.

Abstract: A bone growth promoting composition, comprising a content of at least one substance from the group consisting of the growth factors FGF, TGF-.beta., IGF-II, PDGF and biologically active mutants and fragments thereof and bone extracts with the corresponding activity as well as a bone extract with BMP activity. In combination with an appropriate application material, the use of the composition in the preparation of implant material is also described.

Abstract: Peptides which contain epitopes that mimic epitopes of the amino terminal propeptide of .alpha.1 Type I collagen, and antibodies which bind the epitopes, are useful in monitoring bone formation. Assays which employ the peptides and antibodies thereto are particularly useful in diagnosing and monitoring bone related disorders, such as osteoporosis and Paget's disease, among others.

Abstract: A method for stimulating the production of growth factor in living tissue is provided. The method involves time application of a controlled, fluctuating, directionally oriented magnetic field parallel to a predetermined axis projecting through the target tissue. This method provides a non-invasive technique for mediating tissue growth, maintenance, and repair by stimulating the production of growth factors in the tissue of interest. Because cell growth is stimulated by increased levels of growth factor (such as, for example, insulin-like growth factor-II) the beneficial effect remains and continues after the applied magnetic field is removed. Increases in the production of growth factor in the range of 20 to 50 percent have been observed.

Abstract: A method for stimulating the production of growth factor in living tissue is provided. The method involves the application of a controlled, fluctuating, directionally oriented magnetic field parallel to a predetermined axis projecting through the target tissue. This method provides a non-invasive technique for mediating tissue growth, maintenance, and repair by stimulating the production of growth factors in the tissue of interest. Because cell growth is stimulated by increased levels of growth factor (such as, for example, insulin-like growth factor-II) the beneficial effect remains and continues after the applied magnetic field is removed. Increases in the production of growth factor in the range of 20 to 50 percent have been observed.

Abstract: A pharmaceutical composition for increasing bone mass and preventing loss of bone mass is provided, comprising a fluoride source and a mitogenic hydantoin in combination with a pharmaceutically acceptable carrier, in which the fluoride source provides a molar ratio of fluoride ion to hydantoin in the composition of from about 0.1:1 to about 100:1. The combination is administered to a vertebrate, typically in the form of an orally administratable tablet or capsule.

Abstract: A buccal lozenge medication for providing fluoride ion for the prevention and treatment of bone loss disease. The dosage is a lozenge containing from 20 to 100 milligrams of sodium monofluorophosphate and further including a slow release mechanism for controlling release of the fluoride ion while in the mouth. Up to ten percent of sodium fluoride can be added.

Abstract: A pharmaceutical composition for increasing bone mass and preventing loss of bone mass is provided, comprising a fluoride source and a mitogenic hydantoin in combination with a pharmaceutically acceptable carrier. The combination is administered to a vertebrate, typically in the form of an orally administratable tablet or capsule.

Abstract: A medication for providing fluoride ion for the prevention and treatment of bone loss disease. The dosage is a lozenge, tablet or capsule containing from 20 to 100 milligrams of sodium monofluorophosphate and further includes a slow release mechanism for controlling release of the fluoride ion over a period of up to eight hours after swallowing. Up to ten percent of sodium fluoride can be added.